Physician profile
Joseph King
NPI 1316972938
$4,491.93
in general payments reported to CMS, 2019-2025
28 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $1,089 · 2021: $754 · 2022: $689 · 2023: $456 · 2024: $279 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,060.64 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $650.59 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $450.24 | 2019-2025 | |
| Amarin Pharma, INC. | $287.25 | 2019-2022 | |
| Allergan, INC. | $258.65 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $238.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.18 | 2020-2024 | Xifaxan, Trulance |
| Abbvie INC. | $186.67 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $160.08 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Corcept Therapeutics | $112.18 | 2020-2023 | Korlym |
| Janssen Pharmaceuticals, INC | $106.63 | 2019-2020 | |
| Pfizer INC. | $105.99 | 2023-2025 | |
| Arbor Pharmaceuticals, INC. | $97.30 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $89.78 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $85.41 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $81.52 | 2023 | Azstarys |
| Eisai INC. | $48.33 | 2021 | |
| Esperion Therapeutics, INC. | $43.68 | 2020-2023 | Nexletol |
| Glaxosmithkline, LLC. | $42.33 | 2023 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $41.05 | 2022 | |
| Alkermes, INC. | $24.84 | 2020 | |
| Promius Pharma LLC | $21.45 | 2019 | |
| Merck Sharp & Dohme LLC | $19.99 | 2024 | M-M-R II, Gardasil, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.13 | 2020 | |
| Seqirus USA INC | $14.83 | 2025 | Flucelvax |
| Teva Pharmaceuticals USA, INC. | $12.14 | 2019 | |
| Horizon Therapeutics Plc | $12.13 | 2020 | |
| Antares Pharma, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.